nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-220-12-97-102nogr-2656Research ArticleМИКРОБИОТАMICROBIOTAЭффективность аутопробиотиков в коррекции липидного обменаThe effectiveness of autoprobiotics in the correction of lipid metabolismhttps://orcid.org/0000-0001-7429-0336БарышниковаН. В.BaryshnikovaN. V.baryshnikova_nv@mail.ruАлфероваЛ. С.AlferovaL. S.noemail@neicon.ruhttps://orcid.org/0000-0002-7173-0575ДемченкоЕ. А.DemchenkoE. A.noemail@neicon.ruЛавреноваН. С.LavrenovaN. S.noemail@neicon.ruhttps://orcid.org/0000-0001-7878-6339ЦапиеваА. Н.TsapievaA. N.noemail@neicon.ruhttps://orcid.org/0000-0003-2312-5589СуворовА. Н.SuvorovA. N.noemail@neicon.ruhttps://orcid.org/0000-0002-2569-6660ЕрмоленкоЕ. И.ErmolenkoE. I.noemail@neicon.ruФГБНУ «Институт экспериментальной медицины»; ФГБОУ ВО ПСПбГМУ им. акад. И. П. Павлова Минздрава РоссииРоссияInstitute of Experimental Medicine; Pavlov First St. Petersburg State Medical UniversityRussian FederationФГБНУ «Институт экспериментальной медицины»РоссияInstitute of Experimental MedicineRussian Federation20231812202301297102Copyright © Барышникова Н.В., Алферова Л.С., Демченко Е.А., Лавренова Н.С., Цапиева А.Н., Суворов А.Н., Ермоленко Е.И., 20232023Барышникова Н.В., Алферова Л.С., Демченко Е.А., Лавренова Н.С., Цапиева А.Н., Суворов А.Н., Ермоленко Е.И.Baryshnikova N.V., Alferova L.S., Demchenko E.A., Lavrenova N.S., Tsapieva A.N., Suvorov A.N., Ermolenko E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2656

Цель исследования: оценка эффективности аутопротиотика на основе индигенных энтерококков в коррекции нарушений липидного обмена. Материалы и методы: Под наблюдением находилось 17 пациентов с метаболическим синдромом и дислипидемией. Все пациенты до начала процедур исследования подписали информированное согласие. В качестве персонифицированного функционального пищевого продукта (ПФПП) назначался аутопробиотик (АП) на основе индигенных энтерококков. АП назначался по 50 мл 2 раза в день в течение 20 дней, использовалось 2 курса с интервалом в 1 месяц. Эффективность АП оценивалась по изменению показателей липидного обмена в две временные точки: V1 (до начала лечения), V2 (через 2 недели после окончания второго курса аутопробиотической терапии). Показатели липидного профиля: общий холестерин (ХС), липипротеиды низкой плотности (ЛПНП), липипротеиды очень низкой плотности (ЛПОНП), липипротеиды высокой плотности (ЛПВП), триглицериды (ТГ) оценивались в сыворотке крови натощак в динамике до лечения и через две недели после окончания второго курса аутопробиотиков. В тех же временных точках дополнительно оценивался уровень С-реактивного белка (СРБ) как маркера хронического низкоактивного воспаления, которое может усугубить нарушения липидного профиля у больных метаболическим синдромом. Статистическая обработка проведена с помощью пакета компьютерных программ SPSS8.0. Результаты: После приема аутопробиотика выявлено статистически значимое улучшение большинства анализируемых показателей липидного обмена, а также уменьшение уровня С-реактивного белка. Выводы: аутопробиотики могут быть многообещающим методом коррекции нарушений не только кишечной микробиоты, но и изменений липидного обмена. Актуальным представляется использование комбинации аутопробиотиков со статинами, т. к. при этом будет обеспечиваться воздействие на разные патогенетические пути развития дислипидемии. Однако необходимы дальнейшие исследования, чтобы получить более глубокое понимание лежащих в основе выявленного эффекта механизмов.

Objective: evaluation of the effectiveness of an autoprobiotic based on indigenous enterococci in the correction of lipid metabolism disorders. Materials and Methods: 17 patients with metabolic syndrome and dyslipidemia were under observation. All patients signed an informed consent prior to the start of the study procedures. An autoprobiotic (AP) based on indigenous enterococci was prescribed as a personalized functional food product (PFPP). AP was prescribed 50 ml 2 times a day for 20 days, 2 courses were used with an interval of 1 month. The effectiveness of AP was assessed by changes in lipid metabolism at two time points: V1 (before the start of treatment), V2 (2 weeks after the end of the second course of autoprobiotic therapy). Lipid profile indicators: total cholesterol (CL), low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides (TG) were evaluated in fasting blood serum in dynamics before treatment and two weeks after the end of the second course of autoprobiotics. At the same time points, the level of C-reactive protein (CRP) was additionally assessed as a marker of chronic low-level inflammation, which can aggravate lipid profile disorders in patients with metabolic syndrome. Statistical processing was carried out using the SPSS8.0 computer software package. Results: After taking the autoprobiotic, a statistically significant improvement was revealed in most of the analyzed parameters of lipid metabolism, as well as a decrease in the level of C-reactive protein. (p<0.05). Conclusions: autoprobiotics can be a promising method of correcting disorders not only of the intestinal microbiota, but also changes in lipid metabolism. It seems relevant to use a combination of autoprobiotics with statins, because this will provide an impact on different pathogenetic pathways of dyslipidemia. However, further research is needed to gain a deeper understanding of the underlying mechanisms of the identified effect.

ожирениеаутопробиотикихолестеринлипидымикробиотаobesityautoprobioticscholesterollipidsmicrobiotaReferencesSchoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019, 20(4):461-472. doi: 10.1007/s11154-019-09512-0.Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019, 20(4):461-472. doi: 10.1007/s11154-019-09512-0.Sun C, Wang Z, Hu L, Zhang X, Chen J, Yu Z, Liu L, Wu M. Targets of statins intervention in LDL-C metabolism: Gut microbiota. Front Cardiovasc Med. 2022;9:972603. doi: 10.3389/fcvm.2022.972603.Sun C, Wang Z, Hu L, Zhang X, Chen J, Yu Z, Liu L, Wu M. Targets of statins intervention in LDL-C metabolism: Gut microbiota. Front Cardiovasc Med. 2022;9:972603. doi: 10.3389/fcvm.2022.972603.Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020, 72:558-77. doi: 10.1016/j.jhep.2019.10.003.Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020, 72:558-77. doi: 10.1016/j.jhep.2019.10.003.Martinez KB, Leone V, Chang EB. Western diets, gut dysbiosis, and metabolic diseases: are they linked? Gut Microbes. 2017, 8:130-42. doi: 10.1080/ 19490976.2016.1270811l.Martinez KB, Leone V, Chang EB. Western diets, gut dysbiosis, and metabolic diseases: are they linked? Gut Microbes. 2017, 8:130-42. doi: 10.1080/ 19490976.2016.1270811l.Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016, 535:56-64. doi: 10.1038/nature 18846.Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016, 535:56-64. doi: 10.1038/nature 18846.Rebolledo C, Cuevas A, Zambrano T, Acuña JJ, Jorquera MA, Saavedra K, Martínez C, Lanas F, Serón P, Salazar LA, Saavedra N. Bacterial Community Profile of the Gut Microbiota Differs between Hypercholesterolemic Subjects and Controls. Biomed Res Int. 2017;2017:8127814. doi: 10.1155/2017/8127814.Rebolledo C, Cuevas A, Zambrano T, Acuña JJ, Jorquera MA, Saavedra K, Martínez C, Lanas F, Serón P, Salazar LA, Saavedra N. Bacterial Community Profile of the Gut Microbiota Differs between Hypercholesterolemic Subjects and Controls. Biomed Res Int. 2017;2017:8127814. doi: 10.1155/2017/8127814.Alferova L.S., Ermolenko E. I., Chernikova A. T. et al. Autoprobiotic enterococci as a component of metabolic syndrome complex therapy.Russian Journal for Personalized Medicine. 2022;2(6):98-114. (In Russ.) doi: 10.18705/2782-3806-2022-2-6-98-114.Alferova L.S., Ermolenko E. I., Chernikova A. T. et al. Autoprobiotic enterococci as a component of metabolic syndrome complex therapy.Russian Journal for Personalized Medicine. 2022;2(6):98-114. (In Russ.) doi: 10.18705/2782-3806-2022-2-6-98-114.Liu Y., Song X., Zhou H. et al. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Front Microbiol. 2018 Mar 22;9:530. doi: 10.3389/fmicb.2018.00530.Liu Y., Song X., Zhou H. et al. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Front Microbiol. 2018 Mar 22;9:530. doi: 10.3389/fmicb.2018.00530.Drapkina O.M., Shirobokikh O. E. Role of Gut Microbiota in the Pathogenesis of Cardiovascular Diseases and Metabolic Syndrome. Rational Pharmacotherapy in Cardiology. 2018;14(4):567-574. (In Russ). doi: 10.20996/1819-6446-2018-14-4-567-574.Drapkina O.M., Shirobokikh O. E. Role of Gut Microbiota in the Pathogenesis of Cardiovascular Diseases and Metabolic Syndrome. Rational Pharmacotherapy in Cardiology. 2018;14(4):567-574. (In Russ). doi: 10.20996/1819-6446-2018-14-4-567-574.Kimura I., Ozawa K., Inoue D. et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829. doi: 10.1038/ncomms2852.Kimura I., Ozawa K., Inoue D. et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829. doi: 10.1038/ncomms2852.Kumar P.S., Mason M. R., Brooker M. R., O’Brien K. Pyrosequencing reveals unique microbial signatures associated with healthy and failing dental implants. J Clin Periodontol. 2012;39(5):425-33. doi: 10.1111/j.1600-051X.2012.01856.x.Kumar P.S., Mason M. R., Brooker M. R., O’Brien K. Pyrosequencing reveals unique microbial signatures associated with healthy and failing dental implants. J Clin Periodontol. 2012;39(5):425-33. doi: 10.1111/j.1600-051X.2012.01856.x.Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147-91. doi: 10.1152/physrev.00010.2008.Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147-91. doi: 10.1152/physrev.00010.2008.Schoeler M., Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20(4):461-472. doi: 10.1007/s11154-019-09512-0.Schoeler M., Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20(4):461-472. doi: 10.1007/s11154-019-09512-0.Zhu Y., Li Q., Jiang H. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide. APMIS. 2020;128(5):353-366. doi: 10.1111/apm.13038Zhu Y., Li Q., Jiang H. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide. APMIS. 2020;128(5):353-366. doi: 10.1111/apm.13038Bennett B.J., de Aguiar Vallim T. Q., Wang Z. et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17(1):49-60. doi: 10.1016/j.cmet.2012.12.011.Bennett B.J., de Aguiar Vallim T. Q., Wang Z. et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17(1):49-60. doi: 10.1016/j.cmet.2012.12.011.He X., Zheng N., He J., Liu C., Feng J., Jia W., Li H. Gut Microbiota Modulation Attenuated the Hypolipidemic Effect of Simvastatin in High-Fat/Cholesterol-Diet Fed Mice. J Proteome Res. 2017;16(5):1900-1910. doi: 10.1021/acs.jproteome.6b00984.He X., Zheng N., He J., Liu C., Feng J., Jia W., Li H. Gut Microbiota Modulation Attenuated the Hypolipidemic Effect of Simvastatin in High-Fat/Cholesterol-Diet Fed Mice. J Proteome Res. 2017;16(5):1900-1910. doi: 10.1021/acs.jproteome.6b00984.Yoo D.H., Kim I. S., Van Le T. K., Jung I. H., Yoo H. H., Kim D. H. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 2014;42(9):1508-13. doi: 10.1124/dmd.114.058354.Yoo D.H., Kim I. S., Van Le T. K., Jung I. H., Yoo H. H., Kim D. H. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 2014;42(9):1508-13. doi: 10.1124/dmd.114.058354.Samsonova N.G., Zvenigorodskaia L. A., Cherkashova E. A., Lazebnik L. B. [Intestinal dysbiosis and atherogenic dyslipidemia]. Eksp Klin Gastroenterol. 2010;(3):88-94.Russian. PMID: 20499450Samsonova N.G., Zvenigorodskaia L. A., Cherkashova E. A., Lazebnik L. B. [Intestinal dysbiosis and atherogenic dyslipidemia]. Eksp Klin Gastroenterol. 2010;(3):88-94.Russian. PMID: 20499450Adak A., Khan M. R. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019, 76:473-93. doi: 10.1007/s00018-018-2943-4.Adak A., Khan M. R. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019, 76:473-93. doi: 10.1007/s00018-018-2943-4.Bogiatzi C., Gloor G., Allen-Vercoe E. et al. Metabolic products of the intestinal microbiome and extremes of atherosclerosis. Atherosclerosis. 2018;273:91-97. doi: 10.1016/j.atherosclerosis.2018.04.015.Bogiatzi C., Gloor G., Allen-Vercoe E. et al. Metabolic products of the intestinal microbiome and extremes of atherosclerosis. Atherosclerosis. 2018;273:91-97. doi: 10.1016/j.atherosclerosis.2018.04.015.Nagpal R., Behare P. V., Kumar M. et al. Milk, milk products, and disease free health: an updated overview. Crit Rev Food Sci Nutr. 2012;52(4):321-33. doi: 10.1080/10408398.2010.500231.Nagpal R., Behare P. V., Kumar M. et al. Milk, milk products, and disease free health: an updated overview. Crit Rev Food Sci Nutr. 2012;52(4):321-33. doi: 10.1080/10408398.2010.500231.Falcinelli S., Rodiles A., Hatef A., Picchietti S., Cossignani L., Merrifield D. L., Unniappan S., Carnevali O. Influence of Probiotics Administration on Gut Microbiota Core: A Review on the Effects on Appetite Control, Glucose, and Lipid Metabolism. J Clin Gastroenterol. 2018;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017: S50-S56. doi: 10.1097/MCG.0000000000001064.Falcinelli S., Rodiles A., Hatef A., Picchietti S., Cossignani L., Merrifield D. L., Unniappan S., Carnevali O. Influence of Probiotics Administration on Gut Microbiota Core: A Review on the Effects on Appetite Control, Glucose, and Lipid Metabolism. J Clin Gastroenterol. 2018;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017: S50-S56. doi: 10.1097/MCG.0000000000001064.Mu J., Guo X., Zhou Y., Cao G. The Effects of Probiotics/Synbiotics on Glucose and Lipid Metabolism in Women with Gestational Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Nutrients. 2023;15(6):1375. doi: 10.3390/nu15061375.Mu J., Guo X., Zhou Y., Cao G. The Effects of Probiotics/Synbiotics on Glucose and Lipid Metabolism in Women with Gestational Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Nutrients. 2023;15(6):1375. doi: 10.3390/nu15061375.Kumar M., Nagpal R., Kumar R., Hemalatha R., Verma V., Kumar A., Chakraborty C., Singh B., Marotta F., Jain S., Yadav H. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902917. doi: 10.1155/2012/902917.Kumar M., Nagpal R., Kumar R., Hemalatha R., Verma V., Kumar A., Chakraborty C., Singh B., Marotta F., Jain S., Yadav H. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902917. doi: 10.1155/2012/902917.Suvorov A., Karaseva A., Kotyleva M. et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front. Microbiol. 2018; 9:1869. doi: 10.3389/fmicb.2018.01869.Suvorov A., Karaseva A., Kotyleva M. et al. Autoprobiotics as an approach for restoration of personalised microbiota. Front. Microbiol. 2018; 9:1869. doi: 10.3389/fmicb.2018.01869.Ermolenko E.I., Molostova A. S., Baryshnikova N. V., Svarval A. V., Gladyshev N. S., Kashchenko V. A., Suvorov A. N. The clinical effectiveness of probiotics and autoprobiotics in treatment of Helicobacter pylori-associated dyspepsia.Russian Journal of Infection and Immunity = Infektsiya i immunitet, 2022;12(4):726-734. doi: 10.15789/2220-7619-TCE-1927.Ermolenko E.I., Molostova A. S., Baryshnikova N. V., Svarval A. V., Gladyshev N. S., Kashchenko V. A., Suvorov A. N. The clinical effectiveness of probiotics and autoprobiotics in treatment of Helicobacter pylori-associated dyspepsia.Russian Journal of Infection and Immunity = Infektsiya i immunitet, 2022;12(4):726-734. doi: 10.15789/2220-7619-TCE-1927.Ermolenko E.I., Abdurasulova I. N., Kotyleva M. P., Svirido D. A., Matsulevich A. V., Karaseva A. B. Effects of Indigenous enterococci on the Intestinal Microbiota and the Behavior of Rats. Neuroscience and Behavioral Physiology, 2018, 48(4):496-505. DOI: 10.1007/s11055-018-0591Ermolenko E.I., Abdurasulova I. N., Kotyleva M. P., Svirido D. A., Matsulevich A. V., Karaseva A. B. Effects of Indigenous enterococci on the Intestinal Microbiota and the Behavior of Rats. Neuroscience and Behavioral Physiology, 2018, 48(4):496-505. DOI: 10.1007/s11055-018-0591Simanenkov V.I., Suvorov A. N., Solovyova O. I. A method for obtaining a personalized autoprobiotic product and a method for treating irritable bowel syndrome using this product. RF Patent for invention No. 2546253/ 02.03.2015. Byul. No. 10. Available at: http://www.findpatent.ru/patent/254/2546253.html (accessed on 30 June 2023).Simanenkov V.I., Suvorov A. N., Solovyova O. I. A method for obtaining a personalized autoprobiotic product and a method for treating irritable bowel syndrome using this product. RF Patent for invention No. 2546253/ 02.03.2015. Byul. No. 10. Available at: http://www.findpatent.ru/patent/254/2546253.html (accessed on 30 June 2023).

The authors declare that there are no conflicts of interest present.